Methods of healing wounds and fibrotic disorders using IL-10

• US 7,052,684 B2
• Filed: 02/26/2002
• Issued: 05/30/2006
• Est. Priority Date: 08/09/1995
• Status: Expired due to Fees

• Current Assignee: Armo BioSciences Inc.
• Original Assignee: Renovo Ltd. (Bentley Park Ltd.)
• Inventors: Ferguson, Mark W. J.
• Primary Examiner(s): Landsman, Robert S.
• Application Number:
  US10/082,221
• Publication Number:
  US 20020128447A1
• Time in Patent Office: 1,554 Days
• Field of Search: 424/85.2, 514/2, 530/350, 530/300
• US Class Current: 424/85.1
• CPC Class Codes: A61K 38/2066 IL-10
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention provides IL-10 or a fragment or a partially modified form thereof for use in promoting the healing of wounds and fibrotic disorders with reduced scarring and methods for same.

Claims

1. A method of promoting the healing of a wound, or fibrotic disorder, with reduced scarring, the method comprising administering to a patient in need thereof an amount of an agent selected from the group consisting of:

i) human IL-10, and

ii) a partially modified form of human IL-10, that differs from human IL-10 by the addition, deletion or substitution of at least one amino acid and that has at least 95% homology with human IL-10 and that retains the anti-inflammatory healing functionality of human IL-10,

sufficient to effect said promotion with reduced scarring.

2. The method according to claim 1, wherein the agent is administered in conjunction with a pharmaceutically acceptable carrier, diluent or excipient.

3. The method according to claim 1, wherein the agent is administered in conjunction with a composition for promoting the healing of wounds with reduced scarring.

4. The method according to claim 1, wherein the agent is administered in conjunction with a composition for promoting the healing of chronic wounds.

5. The method according to claim 1, wherein the agent is administered to a wound site or site of a fibrotic disorder.

6. The method according to claim 1, wherein the agent is administered at a concentration of between about 1 μ

M and about 10 μ

M.

7. The method according to claim 6, wherein the agent is administered at a concentration of between about 2.5 μ

M and about 5 μ

M.